Join Growin Stock Community!

Ibio, inc.IBIO.US Overview

US StockHealthcare
(No presentation for IBIO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IBIO AI Insights

IBIO Overall Performance

IBIO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IBIO Recent Performance

-5.67%

Ibio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IBIO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IBIO Key Information

IBIO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IBIO Profile

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Price of IBIO

IBIO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IBIO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
324.71
PB Ratio
1.88
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-8245.67%
Revenue Growth (YoY)
-20.00%
Profit Growth (YoY)
-20.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
324.71
PB Ratio
1.88
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-8245.67%
Revenue Growth (YoY)
-20.00%
Profit Growth (YoY)
-20.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is IBIO's latest earnings report released?

    The most recent financial report for Ibio, inc. (IBIO) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IBIO's short-term business performance and financial health. For the latest updates on IBIO's earnings releases, visit this page regularly.

  • How is IBIO's revenue growth?

    In the latest financial report, Ibio, inc. (IBIO) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IBIO have?

    As of the end of the reporting period, Ibio, inc. (IBIO) had total debt of 2.45M, with a debt ratio of 0.04. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IBIO have?

    At the end of the period, Ibio, inc. (IBIO) held Total Cash and Cash Equivalents of 28.9M, accounting for 0.45 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IBIO's EPS continuing to grow?

    According to the past four quarterly reports, Ibio, inc. (IBIO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IBIO?

    Ibio, inc. (IBIO)'s Free Cash Flow (FCF) for the period is -5.76M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 48.76% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IBIO?

    The latest valuation data shows Ibio, inc. (IBIO) has a Price-To-Earnings (PE) ratio of -3.17 and a Price/Earnings-To-Growth (PEG) ratio of 0.3. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.